Fabhalta (Iptacopan)

Iptacopan is a medicine used to treat paroxysmal nocturnal hemoglobinuria (PNH) and some kidney diseases, like IgA nephropathy and C3 glomerulopathy. It is taken as a pill (capsule) by mouth. It works by blocking part of the immune system called complement that can damage blood cells and the kidneys.

Brand names:Fabhalta
Medication

What people taking Fabhalta (Iptacopan) report

Every report comes from a Lived member, sent anonymously.

Have you tried Fabhalta (Iptacopan) for Paroxysmal Hemoglobinuria?

NameHow it went

About Fabhalta (Iptacopan)

What It's For

Iptacopan, sold as Fabhalta, is a prescription capsule for adults with three uncommon diseases. In each one, part of the immune system called complement is overactive and damages the body's own tissue. In paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder, complement destroys red blood cells, causing anemia, fatigue, dark urine and a higher risk of blood clots. Iptacopan is used both by people starting treatment and by people who still have anemia on injected or infused treatments such as Soliris (eculizumab) or Ultomiris (ravulizumab). It is also approved to slow the loss of kidney function in adults with primary IgA nephropathy (IgAN) who are at risk of their disease getting worse, and to reduce protein in the urine in adults with C3 glomerulopathy (C3G), named for C3, a complement protein that builds up in the kidney. Both are kidney diseases in which immune deposits inflame the kidney's filters. In the kidney studies it was added to blood pressure medicines that protect the kidney (ACE inhibitors or ARBs), not used in place of them. It is not approved for children, and its benefit in C3G that returns after a kidney transplant has not been established.

How It Works

Complement is a chain of proteins in the blood that normally helps destroy germs. One branch of that chain, the alternative pathway, can amplify itself quickly, and in these diseases it attacks the wrong targets: red blood cells in PNH, the kidney's filtering units in IgAN and C3G. Iptacopan blocks factor B, a protein this branch needs to keep amplifying. Because it acts early in the chain, it limits both the destruction of red blood cells inside blood vessels and their removal in the liver and spleen, which is why some people still have anemia on older treatments that act further down. In the kidney diseases, calming this branch reduces inflammation, which shows up as less protein leaking into the urine and, in IgAN, a slower decline in kidney function. The same system helps fight certain bacteria, which explains the drug's main risk.

Dosage & Administration

Iptacopan is taken as a 200 mg capsule twice a day, with or without food. Swallow the capsules whole; do not open, break or chew them. If a dose is missed, take one as soon as possible, even if the next dose is soon, then return to the usual schedule. Before the first dose, vaccines against meningococcal and pneumococcal bacteria need to be completed or updated at least 2 weeks ahead. If treatment must start sooner, antibiotics are prescribed to cover the gap. Boosters may be needed during treatment. Fabhalta is available only through a restricted safety program (a REMS, or Risk Evaluation and Mitigation Strategy), so the prescriber and pharmacy must be enrolled. Patients receive a Patient Safety Card describing infection warning signs, to carry at all times during treatment and for 2 weeks after the last dose. People with PNH switching from an infused medicine start iptacopan within a set window after the last infusion, so the blood is never left unprotected.

Side Effects

In PNH studies, the most common side effects were headache, colds and other nose and throat infections, diarrhea, abdominal pain, nausea and rash. In people with IgAN, abdominal pain, dizziness and nausea were more common than with placebo, and they were mild or moderate. Iptacopan can raise cholesterol and triglycerides (a type of blood fat), so these are checked periodically, and some people need a cholesterol-lowering medicine. Lower platelet counts were also seen in some people with PNH, which blood tests pick up. The most serious risk, infection, is covered under Interactions & Warnings.

Interactions & Warnings

Iptacopan carries a boxed warning, the most prominent warning the US Food and Drug Administration requires, for serious infections caused by encapsulated bacteria, including those that cause meningococcal meningitis, pneumonia and bloodstream infections. These infections can become life-threatening quickly, and vaccination lowers but does not remove the risk. The risk continues for a few weeks after the last dose. It should not be started while someone has an unresolved serious infection of this kind. Get emergency medical care right away for fever with chills, rash, chest pain, cough, fast breathing or a racing heart; headache with fever, a stiff neck or back, nausea or vomiting; confusion; clammy skin; eyes that are sensitive to light; or flu-like body aches. Show the Patient Safety Card to whoever treats you. Gemfibrozil (Lopid), a triglyceride-lowering drug, can raise iptacopan levels and is not recommended with it. Rifampin, an antibiotic used for tuberculosis, can lower iptacopan levels and weaken its effect. Tell the care team about all medicines and supplements, and about any liver disease. The effects on pregnancy are unknown, while untreated PNH and these kidney diseases carry real pregnancy risks, so treatment during pregnancy is weighed case by case. Breastfeeding should stop during treatment and for 5 days after the last dose.

What to Expect

In PNH, blood counts usually improve over the first few months. In the main trial, 51 of 60 people who still had anemia on infused treatment saw their hemoglobin rise substantially without transfusions after switching, compared with none of those who stayed on infusions. Many also reported less fatigue. Regular blood tests track hemoglobin and signs of red cell breakdown. For PNH, iptacopan works only while it is in the body, so taking every dose matters. Missing doses or stopping can let red cell destruction return, with fatigue, dark or red urine, abdominal pain, shortness of breath or trouble swallowing. Contact the care team promptly if these appear, and expect close monitoring for at least 2 weeks after stopping. In IgAN and C3G, change is measured in the lab rather than felt. Protein in the urine typically drops over months; in C3G it fell about a third more than with placebo after 6 months. In IgAN, over two years kidney function declined about half as fast as with placebo. That slows the disease but does not cure it, and treatment is generally long term, with regular urine, kidney function and cholesterol tests.

Questions to Ask Your Doctor

  1. 1.Which vaccines do I need before starting, and when will I need boosters?
  2. 2.What should I do, and where should I go, if I get a fever or other infection signs at night or while traveling?
  3. 3.How will we know if iptacopan is working for my condition, and which tests will we use?
  4. 4.If I have PNH, what is the plan if I miss doses or need to stop?
  5. 5.Could any of my current medicines, including cholesterol drugs, interact with it?

Last reviewed • Oct 2026

Educational content, not medical advice.